BTC-4.92%
Market Analysis
Earnings Review: Legend Bio Beats Expectations, Novartis Deal Ups Revenue
Legend Biotech Corporation reported an EPS of $(0.17) against an expected $(0.26).
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
Key Highlights
- Revenue Surge: Legend Biotech Corporation (NASDAQ: LEGN) reported a significant increase in collaboration revenue, jumping to $75.9 million in Q3 2023 compared to $27.3 million in Q3 2022.
- Earnings Per Share (EPS) Performance: The company reported a net loss of $0.17 per share for Q3 2023, an improvement over the $0.26 per share loss in Q3 2022.
- Strategic Licensing Agreement: Legend Biotech entered into an exclusive global license agreement with Novartis, including a $100 million upfront payment and potential future milestones totaling $1.01 billion.
Legend Biotech Corporation (NASDAQ: LEGN) marked a notable advancement in Q3 2023, primarily highlighted by a substantial increase in collaboration revenue. The reported figure of $75.9 million in Q3 2023 is a significant leap from the $27.3 million recorded in the same quarter of the previous year. This growth is attributed to the increased sales of CARVYKTI® under the Janssen Agreement.
Furthermore, the company strengthened its strategic position through an exclusive global license agreement with Novartis. This deal brings an immediate $100 million upfront payment and opens doors to future milestone payments totaling up to $1.01 billion, significantly bolstering Legend Biotech’s financial and strategic outlook.
Join our Telegram group and never miss a breaking digital asset story.
Financial Performance: Comparing EPS and Revenue against Expectations
Legend Biotech reported an EPS of -$0.17, surpassing expectations of -$0.31. This performance indicates an improvement over the previous year’s Q3 EPS of -$0.26. Moreover, the company’s revenue for the quarter stood at $96.01 million, slightly under the anticipated $97.42 million. This slight shortfall in revenue is offset by the year-over-year growth and the potential future revenues stemming from the Novartis agreement.
Future Outlook: Investment in Research and Operational Expansion
Looking ahead, Legend Biotech is poised for further growth and innovation. With cash reserves of $1.4 billion, the company is well-positioned to fund its operations and capital expenditures through 2025. This financial stability enables continued investment in research and development, as evidenced by the $95.9 million spent in Q3 2023. Additionally, the company’s commitment to expanding its manufacturing capacity and administrative functions indicates a strategic focus on scaling up operations to meet the growing demand for its products, particularly CARVYKTI®.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
